Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

被引:160
作者
Aoki, KR
Guyer, B
机构
[1] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
[2] DuoMed Ltd, Salisbury, Wilts, England
关键词
antigenicity; cervical dystonia; cholinergic; duration; neurotoxin; potency; safety;
D O I
10.1046/j.1468-1331.2001.00035.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Botulinum toxin type A is an important therapeutic agent for the treatment of movement and other disorders. As the clinical uses of botulinum toxin type A expand, it is increasingly important to understand the biochemical and pharmacological actions of this toxin, as well as those of other botulinum toxin serotypes (B-G). Botulinum neurotoxin serotypes exhibit differences in neurotoxin complex protein size, percentage of neurotoxin in the activated or nicked form, intracellular protein target, and potency. These properties differ even between preparations that contain the same botulinum toxin serotype due to variations in product formulations. As demonstrated in preclinical and clinical studies. these differences result in a unique combination of efficacy, duration of action, safety, and antigenic potential for each botulinum neurotoxin preparation.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 79 条
[1]   TERMINAL SPROUTING IN MOUSE NEUROMUSCULAR-JUNCTIONS POISONED WITH BOTULINUM TYPE-A TOXIN - MORPHOLOGICAL AND ELECTROPHYSIOLOGICAL FEATURES [J].
ANGAUTPETIT, D ;
MOLGO, J ;
COMELLA, JX ;
FAILLE, L ;
TABTI, N .
NEUROSCIENCE, 1990, 37 (03) :799-808
[2]  
Aoki KR, 2000, NEUROLOGY, V54, pA199
[3]   Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations [J].
Aoki, KR .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 :S3-S10
[4]   ABSENCE OF ANTIBODY-PRODUCTION IN PATIENTS TREATED WITH BOTULINUM-A TOXIN [J].
BIGLAN, AW ;
GONNERING, R ;
LOCKHART, LB ;
RABIN, B ;
FUERSTE, FH .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 101 (02) :232-235
[5]  
Binder W., 1998, MOV DISORD, V13, P241
[6]  
BINZ T, 1994, J BIOL CHEM, V269, P1617
[7]   INTERACTION OF I-125 LABELED BOTULINUM NEUROTOXINS WITH NERVE-TERMINALS .1. ULTRASTRUCTURAL AUTORADIOGRAPHIC LOCALIZATION AND QUANTITATION OF DISTINCT MEMBRANE ACCEPTORS FOR TYPE-A AND TYPE-B ON MOTOR NERVES [J].
BLACK, JD ;
DOLLY, JO .
JOURNAL OF CELL BIOLOGY, 1986, 103 (02) :521-534
[8]   BOTULINUM TOXIN TREATMENT IN SPASMODIC TORTICOLLIS [J].
BLACKIE, JD ;
LEES, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (08) :640-643
[9]  
BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x
[10]   Botulinum toxin therapy, immunologic resistance, and problems with available materials [J].
Borodic, G ;
Johnson, E ;
Goodnough, M ;
Schantz, E .
NEUROLOGY, 1996, 46 (01) :26-29